BRCA-Associated Protein-1 (BAP1) Loss and Real-World Outcomes of Immune Checkpoint Inhibitor Therapy in Pleural Mesothelioma

被引：0
|
作者：
Smith, C. J. [1 ]
Desai, A. [1 ]
Hazim, A. [1 ]
Dimou, A. [1 ]
Leventakos, K. [1 ]
Molina, J. [1 ]
Parikh, K. [1 ]
Kommalapati, A. [1 ]
Hocum, C. [1 ]
Moffett, J. N. [1 ]
Schwecke, A. [1 ]
Mansfield, A. S. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Mesothelioma; Immunotherapy; BAP1;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP14.04-01
引用
收藏
页码：S726 / S727
页数：2
相关论文
共 7 条
  • [1] Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
    Kim, Roger Y.
    Mitra, Nandita
    Bagley, Stephen J.
    Marmarelis, Melina E.
    Haas, Andrew R.
    Rendle, Katharine A.
    Vachani, Anil
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (06):
  • [2] Loss of BRCA1-associated protein 1 (BAP1) expression is rare in non- small cell lung cancer
    Owen, Daniel
    Sheffield, Brandon S.
    Ionescu, Diana
    Churg, Andrew
    HUMAN PATHOLOGY, 2017, 60 : 82 - 85
  • [3] Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
    Huang, Richard S. P.
    Carbone, David P.
    Li, Gerald
    Schrock, Alexa
    Graf, Ryon P.
    Zhang, Liangliang
    Murugesan, Karthikeyan
    Ross, Jeffrey S.
    Tolba, Khaled
    Sands, Jacob
    Oxnard, Geoffrey R.
    Spigel, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (01)
  • [4] Real-World Treatment Patterns and Outcomes Among Patients With Metastatic NSCLC Previously Treated With Programmed Cell Death Protein-1/ Programmed Death-Ligand 1 Inhibitors
    Bains, Savreet
    Kalsekar, Anu
    Amiri, Katayoun I.
    Weiss, Jared
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (02):
  • [5] Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China
    Shi, Changying
    Li, Yulong
    Yang, Cheng
    Qiao, Liang
    Tang, Liukang
    Zheng, Yuting
    Chen, Xue
    Qian, Youwen
    Yang, Jiamei
    Wu, Dong
    Xie, Feng
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [6] Clinical Outcomes Associated with Monotherapy and Combination Therapy of Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Hepatocellular Carcinoma in Real-World Practice: A Systematic Literature Review and Meta-Analysis
    Zou, Huimin
    Lei, Qing
    Yan, Xin
    Lai, Yunfeng
    Ung, Carolina Oi Lam
    Hu, Hao
    CANCERS, 2023, 15 (01)
  • [7] Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients (≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study
    Yu, Yi
    Wu, Tao
    Gan, Wei
    Liu, Can
    Zhang, Ran
    Zheng, Jinxiu
    Xiong, Jianping
    Chen, Jun
    Li, Junhe
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (09) : 2360 - 2368
1